Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 13
Submit an article Journal homepage
183
Views
0
CrossRef citations to date
0
Altmetric
Review

Pharmacogenetics of Neural Injury Recovery

Kristin M Pearson-Fuhrhop1 Department of Anatomy & Neurobiology, University of California, Irvine, 200 S Manchester Avenue, Suite 206, Orange, CA92868, USA
&
Steven C Cramer1 Department of Anatomy & Neurobiology, University of California, Irvine, 200 S Manchester Avenue, Suite 206, Orange, CA92868, USA;2 Department of Neurology, University of California, Irvine, 200 S Manchester Ave, Suite 206, Orange, CA92868, USA.Correspondence[email protected]
Pages 1635-1643 | Published online: 02 Oct 2013

References

  • del Rio-Espinola A , Fernandez-CadenasI, GiraltD et al. A predictive clinical–genetic model of tissue plasminogen activator response in acute ischemic stroke. Ann. Neurol. 72(5) , 716–729 (2012).
  • Fernandez-Cadenas I , Del Rio-Espinola A, Giralt D et al.IL1B and VWF variants are associated with fibrinolytic early recanalization in patients with ischemic stroke. Stroke43(10) , 2659–2665 (2012).
  • Engelter ST , UrschelerN, BarontiF et al. Frequency and determinants of using pharmacological enhancement in the clinical practice of in-hospital stroke rehabilitation. Eur. Neurol. 68(1) , 28–33 (2012).
  • Scheidtmann K , FriesW, MullerF, KoenigE. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet358 , 787–790 (2001).
  • Floel A , HummelF, BreitensteinC, KnechtS, CohenLG. Dopaminergic effects on encoding of a motor memory in chronic stroke. Neurology65(3) , 472–474 (2005).
  • Rosser N , HeuschmannP, WerschingH, BreitensteinC, KnechtS, FloelA. Levodopa improves procedural motor learning in chronic stroke patients. Arch. Phys. Med. Rehabil.89(9) , 1633–1641 (2008).
  • Chollet F , TardyJ, AlbucherJF et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 10(2) , 123–130 (2011).
  • Jorge RE , RobinsonRG, ArndtS, StarksteinS. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am. J. Psychiatry160(10) , 1823–1829 (2003).
  • Markus HS . Stroke genetics: prospects for personalized medicine. BMC Med.10 , 113 (2012).
  • Ezekowitz MD , AikensTH, BrownA, EllisZ. The evolving field of stroke prevention in patients with atrial fibrillation. Stroke41(10 Suppl.) , S17–S20 (2010).
  • Mega JL , CloseSL, WiviottSD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4) , 354–362 (2009).
  • Anderson JL , HorneBD, StevensSM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22) , 2563–2570 (2007).
  • Mandava P , MurthySB, MunozM et al. Explicit consideration of baseline factors to assess recombinant tissue-type plasminogen activator response with respect to race and sex. Stroke 44(6) , 1525–1531 (2013).
  • Engelter ST . Safety in pharmacological enhancement of stroke rehabilitation. Eur. J. Phys. Rehabil. Med.49(2) , 261–267 (2013).
  • Dam M , ToninP, De Boni A et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke27(7) , 1211–1214 (1996).
  • Pariente J , LoubinouxI, CarelC et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann. Neurol. 50(6) , 718–729 (2001).
  • Zittel S , WeillerC, LiepertJ. Citalopram improves dexterity in chronic stroke patients. Neurorehabil. Neural Repair22(3) , 311–314 (2008).
  • Zittel S , WeillerC, LiepertJ. Reboxetine improves motor function in chronic stroke. A pilot study. J. Neurol.254(2) , 197–201 (2007).
  • Walker-Batson D , SmithP, CurtisS, UnwinH, GreenleeR. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke26(12) , 2254–2259 (1995).
  • Feeney DM , GonzalezA, LawWA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science217(4562) , 855–857 (1982).
  • Martinsson L , HardemarkH, EksborgS. Amphetamines for improving recovery after stroke. Cochrane Database Syst. Rev.1 , CD002090 (2007).
  • Schuster C , MaunzG, LutzK, KischkaU, SturzeneggerR, EttlinT. Dexamphetamine improves upper extremity outcome during rehabilitation after stroke: a pilot randomized controlled trial. Neurorehabil. Neural Repair25(8) , 749–755 (2011).
  • Grade C , RedfordB, ChrostowskiJ, ToussaintL, BlackwellB. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch. Phys. Med. Rehabil.79(9) , 1047–1050 (1998).
  • Lokk J , Salman Roghani R, Delbari A. Effect of methylphenidate and/or levodopa coupled with physiotherapy on functional and motor recovery after stroke – a randomized, double-blind, placebo-controlled trial. Acta Neurol. Scand.123(4) , 266–273 (2011).
  • Delbari A , Salman-RoghaniR, LokkJ. Effect of methylphenidate and/or levodopa combined with physiotherapy on mood and cognition after stroke: a randomized, double-blind, placebo-controlled trial. Eur. Neurol.66(1) , 7–13 (2011).
  • Berthier ML , GreenC, HiguerasC, FernandezI, HinojosaJ, MartinMC. A randomized, placebo-controlled study of donepezil in poststroke aphasia. Neurology67(9) , 1687–1689 (2006).
  • Whyte EM , LenzeEJ, ButtersM et al. An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients. Cerebrovasc. Dis. 26(3) , 317–321 (2008).
  • Sonde L , LokkJ. Effects of amphetamine and/or L-dopa and physiotherapy after stroke – a blinded randomized study. Acta Neurol. Scand.115(1) , 55–59 (2007).
  • Pearson-Fuhrhop KM , MintonB, AcevedoD, ShahbabaB, CramerSC. Genetic variation in the human brain dopamine system influences motor learning and its modulation by L-dopa. PLoS ONE8(4) , e61197 (2013).
  • Becker ML , VisserLE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics12(1) , 79–82 (2011).
  • Kato M , SerrettiA. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry15(5) , 473–500 (2010).
  • Lewis G , MulliganJ, WilesN et al. Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. Br. J. Psychiatry 198(6) , 464–471 (2011).
  • McGuffin P , AlsabbanS, UherR. The truth about genetic variation in the serotonin transporter gene and response to stress and medication. Br. J. Psychiatry198(6) , 424–427 (2011).
  • Hadidi N , Treat-JacobsonDJ, LindquistR. Poststroke depression and functional outcome: a critical review of literature. Heart Lung38(2) , 151–162 (2009).
  • Smits KM , SmitsLJ, SchoutenJS, StelmaFF, NelemansP, PrinsMH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol. Psychiatry9(5) , 433–441 (2004).
  • Kohen R , CainKC, BuzaitisA et al. Response to psychosocial treatment in poststroke depression is associated with serotonin transporter polymorphisms. Stroke 42(7) , 2068–2070 (2011).
  • Pinto N , DolanME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr. Drug Metab.12(5) , 487–497 (2011).
  • Zhong Y , ZhengX, MiaoY, WanL, YanH, WangB. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer‘s disease. Am. J. Med. Sci.345(3) , 222–226 (2013).
  • Albani D , Martinelli Boneschi F, Biella G et al. Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer‘s disease patients. J. Alzheimers Dis.30(4) , 745–749 (2012).
  • Pilotto A , FranceschiM, D‘OnofrioG et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 73(10) , 761–767 (2009).
  • Seripa D , BizzarroA, PilottoA et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer‘s disease. Pharmacogenet. Genomics 21(4) , 225–230 (2011).
  • Samson AL , MedcalfRL. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron50(5) , 673–678 (2006).
  • Tjarnlund-Wolf A , HultmanK, CurtisMA, FaullRL, MedcalfRL, JernC. Allelic imbalance of tissue-type plasminogen activator (t-PA) gene expression in human brain tissue. Thromb. Haemost.105(6) , 945–953 (2011).
  • Ladenvall P , JohanssonL, JanssonJH et al. Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb. Haemost. 87(1) , 105–109 (2002).
  • Jannes J , Hamilton-BruceMA, PilottoL et al. Tissue plasminogen activator -7351C/T enhancer polymorphism is a risk factor for lacunar stroke. Stroke 35(5) , 1090–1094 (2004).
  • Maguire J , ThakkinstianA, LeviC et al. Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 polymorphisms on 90-day ischemic stroke functional outcome: a novel finding. J. Stroke Cerebrovasc. Dis. 20(2) , 134–144 (2011).
  • Depondt C , GodardP, EspelRS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur. J. Neurol.18(9) , 1159–1164 (2011).
  • Tarasova L , KalninaI, GeldnereK et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated Type 2 diabetes patients. Pharmacogenet. Genomics 22(9) , 659–666 (2012).
  • Jekic B , LukovicL, BunjevackiV et al. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur. J. Clin. Pharmacol. 69(3) , 377–383 (2012).
  • Leandro-Garcia LJ , LeskelaS, JaraC et al. Regulatory polymorphisms in β-tubulin iia are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res. 18(16) , 4441–4448 (2012).
  • Kawashima S , UekiY, KatoT et al. Changes in striatal dopamine release associated with human motor-skill acquisition. PLoS ONE 7(2) , e31728 (2012).
  • Kalinderi K , FidaniL, KatsarouZ, BostantjopoulouS. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson‘s disease. Int. J. Clin. Pract.65(12) , 1289–1294 (2011).
  • Fox SH , LangAE. Levodopa-related motor complications – phenomenology. Mov. Disord.23(Suppl. 3) , S509–S514 (2008).
  • Shamy MC , ZaiC, BasileVS, KennedyJL, MullerDJ, MasellisM. Ethical and policy considerations in the application of pharmacogenomic testing for tardive dyskinesia: case study of the dopamine D3 receptor. Curr. Pharmacogenomics Person. Med.9(2) , 94–101 (2011).
  • Pearson-Fuhrhop KM , KleimJA, CramerSC. Brain plasticity and genetic factors. Top. Stroke Rehabil.16(4) , 282–299 (2009).
  • Pearson-Fuhrhop KM , BurkeE, CramerSC. The influence of genetic factors on brain plasticity and recovery after neural injury. Curr. Opin. Neurol.25(6) , 682–688 (2012).
  • Simon RP , MellerR, ZhouA, HenshallD. Can genes modify stroke outcome and by what mechanisms?. Stroke43(1) , 286–291 (2012).
  • Egan MF , KojimaM, CallicottJH et al. The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2) , 257–269 (2003).
  • Chen ZY , PatelPD, SantG et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J. Neurosci. 24(18) , 4401–4411 (2004).
  • Kleim JA , ChanS, PringleE et al. BDNF Val66Met polymorphism is associated with modified experience-dependent plasticity in human motor cortex. Nat. Neurosci.9(6) , 735–737 (2006).
  • Cheeran B , TalelliP, MoriF et al. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J. Physiol. 586(Pt 23) , 5717–5725 (2008).
  • McHughen SA , RodriguezPF, KleimJA et al. BDNF Val66Met polymorphism influences motor system function in the human brain. Cereb. Cortex20(5) , 1254–1262 (2010).
  • McHughen SA , Pearson-FuhrhopK, NgoVK, CramerSC. Intense training overcomes effects of the Val66Met BDNF polymorphism on short-term plasticity. Exp. Brain Res.213(4) , 415–422 (2011).
  • Siironen J , JuvelaS, KanarekK, VilkkiJ, HernesniemiJ, LappalainenJ. The Met allele of the BDNF Val66Met polymorphism predicts poor outcome among survivors of aneurysmal subarachnoid hemorrhage. Stroke38(10) , 2858–2860 (2007).
  • Cramer SC , ProcaccioV. Correlation between genetic polymorphisms and stroke recovery: analysis of the GAIN Americas and GAIN International Studies. Eur. J. Neurol.19(5) , 718–724 (2012).
  • Shimizu E , HashimotoK, IyoM. Ethnic difference of the BDNF 196G/A (Val66Met) polymorphism frequencies: the possibility to explain ethnic mental traits. Am. J. Med. Genet. B Neuropsychiatr. Genet.126(1) , 122–123 (2004).
  • Mahley RW , RallSC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet.1 , 507–537 (2000).
  • Cedazo-Minguez A . Apolipoprotein E and Alzheimer‘s disease: molecular mechanisms and therapeutic opportunities. J. Cell. Mol. Med.11(6) , 1227–1238 (2007).
  • Corder EH , SaundersAM, StrittmatterWJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer‘s disease in late onset families. Science 261(5123) , 921–923 (1993).
  • Hyman BT , Gomez-IslaT, RebeckGW et al. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer‘s disease. Ann. NY Acad. Sci. 802 , 1–5 (1996).
  • Ponsford J , McLarenA, SchonbergerM et al. The association between apolipoprotein E and traumatic brain injury severity and functional outcome in a rehabilitation sample. J. Neurotrauma 28(9) , 1683–1692 (2011).
  • Zhou W , XuD, PengX, ZhangQ, JiaJ, CrutcherKA. Meta-analysis of APOE4 allele and outcome after traumatic brain injury. J. Neurotrauma25(4) , 279–290 (2008).
  • Marousi S , EllulJ, AntonacopoulouA, GogosC, PapathanasopoulosP, KarakantzaM. Functional polymorphisms of interleukin 4 and interleukin 10 may predict evolution and functional outcome of an ischaemic stroke. Eur. J. Neurol.18(4) , 637–643 (2011).
  • Weaver SM , ChauA, PortelliJN, GrafmanJ. Genetic polymorphisms influence recovery from traumatic brain injury. Neuroscientist18(6) , 631–644 (2012).
  • Floresco SB , JentschJD. Pharmacological enhancement of memory and executive functioning in laboratory animals. Neuropsychopharmacology36(1) , 227–250 (2011).
  • Husain M , MehtaMA. Cognitive enhancement by drugs in health and disease. Trends Cogn. Sci.15(1) , 28–36 (2011).
  • Meschia JF . Pharmacogenetics and stroke. Stroke40(11) , 3641–3645 (2009).
  • Chan A , PirmohamedM, ComabellaM. Pharmacogenomics in neurology: current state and future steps. Ann. Neurol.70(5) , 684–697 (2011).
  • Shuldiner AR , O‘ConnellJR, BlidenKP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8) , 849–857 (2009).
  • Li Y , TangHL, HuYF, XieHG. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J. Thromb. Haemost.10(2) , 199–206 (2012).
  • Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O‘Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA ‘boxed warning‘: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol.56(4) , 321–341 (2010).
  • Sibbing D , BernlochnerI, KastratiA, PareG, EikelboomJW. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. Circ. Cardiovasc. Interv.4(5) , 505–513; discussion 513 (2011).
  • Pare G , EikelboomJW, SibbingD, BernlochnerI, KastratiA. Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention. Circ. Cardiovasc. Interv.4(5) , 514–521; discussion 521 (2011).
  • Wadelius M , PirmohamedM. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J.7(2) , 99–111 (2007).
  • Cooper GM , JohnsonJA, LangaeeTY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112(4) , 1022–1027 (2008).
  • Takeuchi F , McGinnisR, BourgeoisS et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3) , e1000433 (2009).
  • Daneshjou R , TatonettiNP, KarczewskiKJ et al. Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics 14(Suppl. 3) , S11 (2013).
  • Perera MA , CavallariLH, LimdiNA et al. Genetic variants associated with warfarin dose in African–American individuals: a genome-wide association study. Lancet doi:10.1016/S0140-6736(13)60681-9 (2013) (Epub ahead of print).
  • Lewis JP , RyanK, O‘ConnellJR, et al. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ. Cardiovasc. Genet.6(2) , 184–192 (2013).
  • Al-Azzam SI , AlzoubiKH, KhabourOF, TawalbehD, Al-AzzehO. The contribution of platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2G-765C) polymorphisms to platelet response in patients treated with aspirin. Gene526(2) , 118–121 (2013).
  • Giacino JT , WhyteJ, BagiellaE et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N. Engl. J. Med. 366(9) , 819–826 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.